Source : Biome Australia
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Biome Australia (ASX:BIO) starts delivering its first allocation of Activated Probiotics into pharmacy and health retail stores across the UK and Ireland
  • The allocation follows the recent signing of commercial agreements with UK-based CLF and Ireland-based iiHealthfood, which are to be stocked across the regions
  • The European launch builds on BIO’s success in the Australian market, where it applied an education model and practitioner-only distribution
  • Through commercial testing of both markets, Biome acquires a strong foundational customer and revenue base to be confident that both markets have been de-risked
  • BIO shares are up 14.6 per cent, trading at 27.5 cents at 2:22 pm AEDT

Biome Australia (ASX:BIO) has started delivering its first allocation of Activated Probiotics into pharmacy and health retail stores across the United Kingdom and the Republic of Ireland.

The allocation follows the recent signing of commercial agreements with UK-based CLF and Ireland-based iiHealthfood, intended to be stocked at multiple distribution centres for nationwide consumption.

The European launch builds on the company’s success with activated probiotics in the Australian market, where it applied an education model and practitioner-only distribution. Biome’s team intends to manage all aspects of training, support and customer service to ensure the sales model is consistent with the Australian market.

“This is a significant achievement and demonstrates our ability to both execute and scale into new international markets,” BIO Managing Director and founder Blair Norfolk said.

“We are confident that we have the right elements in place for these markets to add material value to the Biome business over coming years and will also strengthen our ability to support new patients, improve their health outcomes, and quality of life and make our products accessible to all – that remains our core mission.”

Following a successful test market phase in both countries with a focus on independent health practitioners, Biome has acquired a strong foundational customer and revenue base to be confident that both markets have been sufficiently de-risked.

BIO shares were up 14.6 per cent, trading at 27.5 cents at 2:22 pm AEDT.

BIO by the numbers
More From The Market Online
The Market Online Video

Daily ASX Market Close: Late run sees market lift 1%, May 31, 2024

The ASX200 took a late uptick to be add almost a per cent at close this…

Little Green Pharma’s cannabis sales leap 30%

Little Green Pharma saw sales leap 30% to $25.6 million in the financial year to March…

Week 22 Wrap: ASX200 anxious; Macquarie see June correction in US markets

The Australian Bureau of Statistics (ABS) has released Australia's latest retail data, showing growth is up…